| For: | Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M. Emerging role of Janus kinase inhibitors in ulcerative colitis management. World J Gastrointest Pharmacol Ther 2025; 16(4): 110472 [PMID: 41378070 DOI: 10.4292/wjgpt.v16.i4.110472] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v16/i4/110472.htm |
| Number | Citing Articles |
| 1 |
Okasha Zulfiqar, Talha Ali, Ghulam Mohayy Ud Din, Zaheer Ud Din Babar, Shabir Zarif. Oral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials. Cureus 2026; doi: 10.7759/cureus.109528
|
| 2 |
Bhargav Mahabaleshwara Hegde, Rashmi N G. Redox-responsive oral drug delivery systems for inflammatory bowel disease: Analytical challenges, design strategies, and translational outlook. European Journal of Pharmaceutical Sciences 2026; 224 doi: 10.1016/j.ejps.2026.107577
|
| 3 |
Qing Li, Mingrong Cheng, Xiaoyue Wang, Weiwei Li, Feng Zhang. Unraveling the drug resistance web in IBD: The gut microbiota-immunity-epigenetics axis. Gut Microbes 2026; 18(1) doi: 10.1080/19490976.2026.2725430
|